Fusion Antibodies PLC - contract research organisation based in Belfast - Appoints Richard Jones as chief executive to replace Paul Kerr, who is stepping down with immediate effect to pursue other opportunities. Kerr will continue to work for Fusion Antibodies on a consultancy basis. Jones was previously the CEO of BrYet Ltd, a biotech company focused on the discovery and development of transtherapeutics nanotechnology for the treatment of metastatic liver and lung cancers.
"Richard joins us at an exciting time as we focus on the commercial roll out of OptiMAL, our mammalian antibody library and, in particular, on opportunities to develop Covid-19 targets as well as our oncology targets," says Chair Simon Douglas.
Additionally, Kerr is exercising options for 125,000 shares at a price of 4 pence each, with the new shares admitted for trading on Friday.
Current stock price: 130.00 pence
Year-to-date change: up 4.8%
By Zoe Wickens; zoewickens@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Fusion Antibody (FAB)